Biocon partners with Libbs for the sale of generics in Brazil

Home/Pharma News | Posted 16/04/2021 post-comment0 Post your comment

India-based biologicals specialist Biocon has formed an out-licensing agreement with Brazil-based company Libbs Farmaceutica for the sale of generic drugs in the country, marking Biocon’s entry into the Latin American market for generics.

47 MD001813

Biocon Pharma, a subsidiary of India-based biologicals specialist Biocon, announced on 29 March 2021 a partnership with Libbs Farmaceutica (Libbs) of Brazil. Through the partnership, Biocon aims to increase its share of the generic drug market in Latin America.

Biocon first started working with Libbs in 2017 for the launch of their trastuzumab similar in Brazil, where it became a market leader. Trastuzumab is a biological drug, sold under the brand name Herceptin by the originator firm, which is used to treat certain forms of breast and stomach cancer.

The new deal between the two companies relates specifically to generic drugs. Under the partnership, Biocon Pharma will be responsible for the development and manufacturing of generics, while Libbs will import, distribute and market the drugs in Brazil. All drugs will first need to be approved by the Brazilian Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA).

Mr Siddharth Mittal, CEO and Managing Director of Biocon, said of the deal: ‘Expanding our association with Libbs Farmaceutica, a trusted partner, to our generic formulations, will help us establish a firm footing in Latin America, starting with Brazil’.

Mr Alcebíades de Mendonça Athayde Junior, Executive President of Libbs, added: ‘We will now continue making a difference in people’s lives with Biocon, with the goal to expand access to quality, safe and effective treatments to our patients’.

In other news for Biocon, the biologicals arm of the company recently partnered with a number of international organizations, including the Clinton Health Access Initiative, to improve access to cancer and diabetes treatments worldwide [1]. Their own insulin aspart biosimilar Kixelle, developed with Mylan (now part of Viatris), was recently approved by the European Commission to be sold in the European Union [2].

Related articles
Biocon and Lupin launch generic tacrolimus capsules in US

Brazil publishes pathway for accelerating innovation: the National Strategy of Intellectual Property

Similar biotherapeutic products approved and marketed in Latin America


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. GaBI Online - Generics and Biosimilars Initiative. Biocon Biologics partners to improve global access to cancer treatments and insulin []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 16]. Available from: 
2. GaBI Online - Generics and Biosimilars Initiative. EC approval for insulin aspart biosimilar Kixelle []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 16]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Biocon

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010